SATO VICKI L 4

What Happened

• Vicki L. Sato, a director of Allogene Therapeutics, was granted 95,400 restricted stock units (RSUs) on 2026-06-18. The Form 4 reports the award as an acquisition (code A) at $0.00 (non‑cash equity award). Each RSU represents a contingent right to one share of common stock.

Key Details

• Transaction date: 2026-06-18; Form 4 filed: 2026-06-23.
• Award: 95,400 RSUs; reported price on Form 4: $0.00 (award/derivative).
• Vesting: RSUs vest in two equal semi‑annual installments over one year from the grant date (see footnote).
• Shares owned after transaction: not specified in the filing.
• Filing timeliness: Form 4 was filed on 2026-06-23 for a 2026-06-18 grant (SEC Form 4s are typically due within two business days; this filing appears one business day past that window).

Context

• RSUs are a promise to deliver shares in the future subject to vesting and continued service; they are not an immediate cash purchase or sale. Grants to directors are a common form of compensation and do not, by themselves, indicate a buy or sell decision in the market.